Almac Diagnostics has been trading for over 15 years and was initially founded as a spin out company from Queen’s University Belfast in 2002 called ArraDx.
In 2004, ArraDx was incorporated into the Almac Group under the direction of Sir Allen McClay and became Almac Diagnostics. It was a vision of the Almac Group to have a Diagnostics division to support the growing need for Diagnostics services and to enable the delivery of precision medicine globally.
Since that time Almac Diagnostics has continued to grow and evolve as a business focussed on personalised medicine and complex diagnostic and companion diagnostic tests.
In terms of Regulatory Standards, Almac Diagnostics has held CLIA Lab Accreditation since 2011 and CAP Accreditation since 2012. We also received our New York State Permit (CLEP) in 2013. We were also awarded several other US State permits between 2011 and 2016 including Pennsylvania, California, Florida, Maryland and Rhode Island.
In terms of Quality ISO certification Almac Diagnostics was awarded ISO 17025 in 2005, ISO 13485 in 2015 and ISO 15189 in 2017.
Almac Diagnostics expanded laboratory capabilities by setting up a new laboratory in Durham, North Carolina, USA, in 2016. We continue to expand our range of platform options for clients and have strong partnership agreements in place with key providers for significant periods of time, including Illumina, Thermo Fisher, Nanostring and Qiagen.
Almac Diagnostic’s growth trajectory aligns with increasing global demand for our offering. We continue to expand our range of services to Pharma and Biotech clients and add to our own internal R&D assay pipeline. We have won several awards along the way for our science and innovation capabilities. Most notably the UKTI Award for Innovation as part of the European Business Awards, the ‘R&D Development Achievement Award’ for our DDRD Assay as part of the Irish Pharma Industry Awards and finally the ‘Excellence in Technology’ award as part of the Belfast Telegraph Business Awards.
Almac Diagnostics Customised CDx approach has attracted many successful Companion Diagnostic (CDx) partnerships over the years and we look forward to the future by increasing our partnerships with Pharma and Biotech companies globally.